Cornerstone Wealth Group LLC Has $12.49 Million Stock Holdings in AbbVie Inc. $ABBV

14 Oct 2025, 10:54 by Scott Moore · The Cerbat Gem

Cornerstone Wealth Group LLC grew its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 2.4% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 67,304 shares of the company’s stock after purchasing an additional 1,571 shares during the period. AbbVie comprises approximately 0.9% of Cornerstone Wealth Group LLC’s holdings, making the stock its 22nd biggest holding. Cornerstone Wealth Group LLC’s holdings in AbbVie were worth $12,493,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. NorthRock Partners LLC boosted its stake in shares of AbbVie by 2.3% in the 2nd quarter. NorthRock Partners LLC now owns 76,797 shares of the company’s stock valued at $14,253,000 after purchasing an additional 1,759 shares in the last quarter. Verdence Capital Advisors LLC raised its holdings in shares of AbbVie by 4.2% in the second quarter. Verdence Capital Advisors LLC now owns 27,317 shares of the company’s stock valued at $5,071,000 after buying an additional 1,099 shares during the last quarter. Westchester Capital Management Inc. raised its holdings in shares of AbbVie by 1.0% in the second quarter. Westchester Capital Management Inc. now owns 104,790 shares of the company’s stock valued at $19,451,000 after buying an additional 1,010 shares during the last quarter. Oregon Public Employees Retirement Fund raised its holdings in shares of AbbVie by 0.7% in the second quarter. Oregon Public Employees Retirement Fund now owns 152,736 shares of the company’s stock valued at $28,351,000 after buying an additional 1,100 shares during the last quarter. Finally, Wealth Architects LLC raised its holdings in shares of AbbVie by 1.8% in the second quarter. Wealth Architects LLC now owns 4,694 shares of the company’s stock valued at $871,000 after buying an additional 83 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Performance

Shares of ABBV stock opened at $230.36 on Tuesday. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.74 and a quick ratio of 0.61. The stock has a market cap of $406.94 billion, a PE ratio of 109.70, a price-to-earnings-growth ratio of 1.42 and a beta of 0.51. The stock has a 50-day moving average of $215.50 and a 200-day moving average of $196.89. AbbVie Inc. has a one year low of $163.81 and a one year high of $244.81.

AbbVie (NYSE:ABBV – Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The company reported $2.97 EPS for the quarter, missing analysts’ consensus estimates of $3.24 by ($0.27). The company had revenue of $15.42 billion during the quarter, compared to the consensus estimate of $14.93 billion. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The business’s revenue was up 6.6% compared to the same quarter last year. During the same period last year, the company earned $2.65 earnings per share. As a group, sell-side analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 14th. Investors of record on Wednesday, October 15th will be given a $1.64 dividend. The ex-dividend date is Wednesday, October 15th. This represents a $6.56 annualized dividend and a dividend yield of 2.8%. AbbVie’s payout ratio is currently 312.38%.

Insider Activity at AbbVie

In related news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total value of $8,407,055.40. Following the completion of the transaction, the executive vice president directly owned 177,292 shares in the company, valued at approximately $35,178,278.64. The trade was a 19.29% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Nicholas Donoghoe sold 13,295 shares of the business’s stock in a transaction that occurred on Tuesday, August 5th. The shares were sold at an average price of $198.51, for a total value of $2,639,190.45. Following the completion of the transaction, the executive vice president owned 58,247 shares of the company’s stock, valued at $11,562,611.97. This represents a 18.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.08% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on ABBV. Raymond James Financial reaffirmed an “outperform” rating on shares of AbbVie in a report on Monday, August 25th. Daiwa Capital Markets raised AbbVie from a “neutral” rating to an “outperform” rating and set a $214.00 price objective for the company in a report on Thursday, August 7th. Morgan Stanley boosted their price objective on AbbVie from $250.00 to $255.00 and gave the stock an “overweight” rating in a report on Friday, August 1st. Piper Sandler boosted their price objective on AbbVie from $231.00 to $284.00 and gave the stock an “overweight” rating in a report on Friday. Finally, Bank of America boosted their price objective on AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $231.90.

Read Our Latest Report on ABBV

AbbVie Profile

(Free Report)

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.